Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE ‑2 Trial of Reproxalap in Allergic Conjunctivitis
Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (P<0.0001)
Statistical Significance Achieved for Key Secondary Endpoint of Ocular Redness (P=0.004)
Statistical Significance Achieved for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Allergy & Immunology | Conjunctivitis | Drugs & Pharmacology | New Drug Applications | Statistics